118 related articles for article (PubMed ID: 34533670)
21. H19 serves as a diagnostic biomarker and up-regulation of H19 expression contributes to poor prognosis in patients with gastric cancer.
Chen JS; Wang YF; Zhang XQ; Lv JM; Li Y; Liu XX; Xu TP
Neoplasma; 2016; 63(2):223-30. PubMed ID: 26774144
[TBL] [Abstract][Full Text] [Related]
22. HER2-positive gastric cancer with concomitant MET and/or EGFR overexpression: a distinct subset of patients for dual inhibition therapy.
Ha SY; Lee J; Jang J; Hong JY; Do IG; Park SH; Park JO; Choi MG; Sohn TS; Bae JM; Kim S; Kim M; Kim S; Park CK; Kang WK; Kim KM
Int J Cancer; 2015 Apr; 136(7):1629-35. PubMed ID: 25157953
[TBL] [Abstract][Full Text] [Related]
23. A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation.
Prat A; Guarneri V; Paré L; Griguolo G; Pascual T; Dieci MV; Chic N; González-Farré B; Frassoldati A; Sanfeliu E; Cejalvo JM; Muñoz M; Bisagni G; Brasó-Maristany F; Urso L; Vidal M; Brandes AA; Adamo B; Musolino A; Miglietta F; Conte B; Oliveira M; Saura C; Pernas S; Alarcón J; Llombart-Cussac A; Cortés J; Manso L; López R; Ciruelos E; Schettini F; Villagrasa P; Carey LA; Perou CM; Piacentini F; D'Amico R; Tagliafico E; Parker JS; Conte P
Lancet Oncol; 2020 Nov; 21(11):1455-1464. PubMed ID: 33152285
[TBL] [Abstract][Full Text] [Related]
24. Multicenter large-scale study of prognostic impact of HER2 expression in patients with resectable gastric cancer.
Kurokawa Y; Matsuura N; Kimura Y; Adachi S; Fujita J; Imamura H; Kobayashi K; Yokoyama Y; Shaker MN; Takiguchi S; Mori M; Doki Y
Gastric Cancer; 2015 Oct; 18(4):691-7. PubMed ID: 25224659
[TBL] [Abstract][Full Text] [Related]
25. TFF3 and HER2 expression and their correlation with survival in gastric cancer.
Gu J; Zheng L; Zhang L; Chen S; Zhu M; Li X; Wang Y
Tumour Biol; 2015 Apr; 36(4):3001-7. PubMed ID: 25514872
[TBL] [Abstract][Full Text] [Related]
26. [Value of tumor deposits in staging and prognostic evaluation in gastric cancer patients].
Liang W; Zhou Z; Cui J; Xi H; Chen L
Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Mar; 20(3):277-282. PubMed ID: 28338160
[TBL] [Abstract][Full Text] [Related]
27. HER2 Status in Premalignant, Early, and Advanced Neoplastic Lesions of the Stomach.
Ieni A; Barresi V; Rigoli L; Caruso RA; Tuccari G
Dis Markers; 2015; 2015():234851. PubMed ID: 26494937
[TBL] [Abstract][Full Text] [Related]
28. Clinic-Pathological Characteristics and Prognostic Value of PD-L1 and HER2 in Gastric Cancer.
Chen L; Wang L; Li X; Zhang G; Li Z; Wang Y
DNA Cell Biol; 2021 Feb; 40(2):405-413. PubMed ID: 33605797
[TBL] [Abstract][Full Text] [Related]
29. Prognostic implications of altered human epidermal growth factor receptors (HERs) in gastric carcinomas: HER2 and HER3 are predictors of poor outcome.
Begnami MD; Fukuda E; Fregnani JH; Nonogaki S; Montagnini AL; da Costa WL; Soares FA
J Clin Oncol; 2011 Aug; 29(22):3030-6. PubMed ID: 21709195
[TBL] [Abstract][Full Text] [Related]
30. Prognostic impact of HER2, EGFR, and c-MET status on overall survival of advanced gastric cancer patients.
Fuse N; Kuboki Y; Kuwata T; Nishina T; Kadowaki S; Shinozaki E; Machida N; Yuki S; Ooki A; Kajiura S; Kimura T; Yamanaka T; Shitara K; Nagatsuma AK; Yoshino T; Ochiai A; Ohtsu A
Gastric Cancer; 2016 Jan; 19(1):183-91. PubMed ID: 25682441
[TBL] [Abstract][Full Text] [Related]
31. [Prognostic factors of lymph node-negative metastasis gastric cancer].
Sun D; Xu H; Huang J
Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Feb; 20(2):190-194. PubMed ID: 28226354
[TBL] [Abstract][Full Text] [Related]
32. VEGF and cortactin expression are independent predictors of tumor recurrence following curative resection of gastric cancer.
Wang X; Cao W; Mo M; Wang W; Wu H; Wang J
J Surg Oncol; 2010 Sep; 102(4):325-30. PubMed ID: 20589712
[TBL] [Abstract][Full Text] [Related]
33. Clinicopathological and prognostic significance of HER2 overexpression in gastric cancer: a meta-analysis of the literature.
Liang JW; Zhang JJ; Zhang T; Zheng ZC
Tumour Biol; 2014 May; 35(5):4849-58. PubMed ID: 24449506
[TBL] [Abstract][Full Text] [Related]
34. Monitoring the HER2 copy number status in circulating tumor DNA by droplet digital PCR in patients with gastric cancer.
Shoda K; Ichikawa D; Fujita Y; Masuda K; Hiramoto H; Hamada J; Arita T; Konishi H; Komatsu S; Shiozaki A; Kakihara N; Okamoto K; Taniguchi H; Imoto I; Otsuji E
Gastric Cancer; 2017 Jan; 20(1):126-135. PubMed ID: 26874951
[TBL] [Abstract][Full Text] [Related]
35. Prognostic significance of the neutrophil-to-lymphocyte and platelet-to-lymphocyte ratio in patients with metastatic gastric cancer.
Zhao G; Liu N; Wang S; Guo J; Song X; Qi Y; Qiu W; Lv J
Medicine (Baltimore); 2020 Mar; 99(10):e19405. PubMed ID: 32150090
[TBL] [Abstract][Full Text] [Related]
36. Prognostic analysis of stage III gastric cancer after curative surgery according to the newest TNM classification.
Wei J; Yao T; Wang Y; Li L; Pan C; Zhang N
Clin Transl Oncol; 2019 Feb; 21(2):232-238. PubMed ID: 29968135
[TBL] [Abstract][Full Text] [Related]
37. Lnc RNA HOTAIR functions as a competing endogenous RNA to regulate HER2 expression by sponging miR-331-3p in gastric cancer.
Liu XH; Sun M; Nie FQ; Ge YB; Zhang EB; Yin DD; Kong R; Xia R; Lu KH; Li JH; De W; Wang KM; Wang ZX
Mol Cancer; 2014 Apr; 13():92. PubMed ID: 24775712
[TBL] [Abstract][Full Text] [Related]
38. Impact of expression of human epidermal growth factor receptors EGFR and ERBB2 on survival in stage II/III gastric cancer.
Terashima M; Kitada K; Ochiai A; Ichikawa W; Kurahashi I; Sakuramoto S; Katai H; Sano T; Imamura H; Sasako M;
Clin Cancer Res; 2012 Nov; 18(21):5992-6000. PubMed ID: 22977193
[TBL] [Abstract][Full Text] [Related]
39. [Evaluation of the value of 7th editions of UICC-AJCC esophageal and gastric cancer TNM staging systems for prognostic prediction of adenocarcinoma of esophagogastric junction (Siewert type II)].
Shi GD; Luo ZL; Fu MY; Tian D; Zhang L; Zhang KP
Zhonghua Zhong Liu Za Zhi; 2014 Dec; 36(12):916-21. PubMed ID: 25623766
[TBL] [Abstract][Full Text] [Related]
40. Alterations in the human epidermal growth factor receptor 2-phosphatidylinositol 3-kinase-v-Akt pathway in gastric cancer.
Sukawa Y; Yamamoto H; Nosho K; Kunimoto H; Suzuki H; Adachi Y; Nakazawa M; Nobuoka T; Kawayama M; Mikami M; Matsuno T; Hasegawa T; Hirata K; Imai K; Shinomura Y
World J Gastroenterol; 2012 Dec; 18(45):6577-86. PubMed ID: 23236232
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
